{
    "clinical_study": {
        "@rank": "67017", 
        "arm_group": [
            {
                "arm_group_label": "KHK4827 70mg SC", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KHK4827 140mg SC", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KHK4827 210mg SC", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo SC", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to  evaluate the efficacy and safety of KHK4827 in subjects with\n      moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled,\n      parallel group study. Pharmacokinetics of KHK4827 will also be assessed."
        }, 
        "brief_title": "A Phase 2 Clinical Study of KHK4827", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Moderate to Severe Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has had stable moderate to severe plaque psoriasis for at least 6 months.\n\n          -  Subject has received at least one previous phototherapy or systemic psoriasis therapy\n             or has been a candidate to receive phototherapy or systemic psoriasis therapy in the\n             opinion of the investigator.\n\n          -  Subject has involved BSA \u2265 10% and PASI \u2265 12 at screening and at baseline.\n\n        Exclusion Criteria:\n\n          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis,\n             medication-induced, or medication-exacerbated psoriasis.\n\n          -  Evidence of skin conditions at the time of the screening visit (eg, eczema) that\n             would interfere with evaluations of the effect of investigational product on\n             psoriasis.\n\n          -  Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2\n             or higher infection\n\n          -  Subject has a significant concurrent medical condition or laboratory abnormalities,\n             as defined in the study protocol.\n\n          -  Subject has used the following therapies within 14 days of the first dose: topical\n             calcineurin inhibitors including tacrolimus\n\n             , topical vitamin A, activated form D3 or activated form D3 analogue preparations,\n             weak through strong topical steroids (excluding application on the scalp, axillae,\n             and groin)\n\n          -  Subject has used the following therapies within 28 days of the first dose:  any other\n             systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates,\n             steroids), UVA therapy (with or without psoralen), very strong or strongest topical\n             steroid, tar therapy\n\n          -  Subject has used the following therapies within 3 months of the first dose:\n             adalimumab,  etanercept, infliximab,  or live vaccines\n\n          -  Subject has used ustekinumab within 6 months of the first dose\n\n          -  Subject has previously used an anti-interleukin-17 biologic therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748539", 
            "org_study_id": "4827-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "KHK4827 70mg SC", 
                    "KHK4827 140mg SC", 
                    "KHK4827 210mg SC"
                ], 
                "intervention_name": "KHK4827", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo SC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chiyoda-ku", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percent improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PASI 75 at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "PASI 50, 90 and 100 at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Static physician's global assessment (sPGA) of \"clear or almost clear (0 or 1)\" at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "sPGA of \"clear (0)\" at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Body surface area involvement (BSA) of lesion at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "American College of Rheumatology (ACR) 20% response (only in subjects with psoriasis arthritis)at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Incidence and types of adverse events and adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Profiles of Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}